decr-1.3 Antibody

What is DECR-1 and why is it significant in metabolic research?

DECR-1 (2,4-DiEnol CoA Reductase, mitochondrial) is a 33-36 kDa member of the DECR subfamily within the short-chain dehydrogenase/reductase family. This mitochondrial enzyme is expressed in multiple cell types, particularly those involved in oxidative degradation of fatty acids. DECR-1 plays a critical role in converting unsaturated fatty acids with two double bonds into substrates with one double bond, which subsequently undergo isomerization before entering the beta-oxidation cycle . The enzyme's central position in fatty acid metabolism makes it valuable for studying mitochondrial function, metabolic disorders, and energy production pathways.

In which tissue types can DECR-1 expression be reliably detected?

Western blot analysis demonstrates that DECR-1 can be reliably detected in human kidney tissue, human pancreas tissue, and human liver tissue . These tissues exhibit high metabolic activity and energy requirements, consistent with DECR-1's role in fatty acid oxidation. When designing experiments, researchers should consider these tissues as positive controls for antibody validation and expression studies.

What are the optimal storage conditions for maintaining DECR-1.3 antibody integrity?

For maximum antibody stability and performance:

• Use a manual defrost freezer and avoid repeated freeze-thaw cycles

• Store unopened antibody at -20 to -70°C for up to 12 months from receipt date

• After reconstitution, store at 2 to 8°C under sterile conditions for up to 1 month

• For long-term storage after reconstitution, keep at -20 to -70°C under sterile conditions for up to 6 months

Proper storage is critical for maintaining binding affinity and specificity, especially for applications requiring quantitative analysis.

What methodological approaches provide optimal DECR-1 detection in Western blot applications?

For optimal Western blot detection:

• Use PVDF membrane for protein transfer

• Apply the antibody at 0.25 μg/mL concentration

• Follow with an appropriate HRP-conjugated secondary antibody (e.g., Anti-Sheep IgG)

• Conduct the experiment under reducing conditions

• Use appropriate buffer systems (e.g., Immunoblot Buffer Group 1)

This methodology reliably detects DECR-1 as a specific band at approximately 34 kDa. Researchers should optimize antibody concentration through titration experiments to achieve the best signal-to-noise ratio for their specific samples.

What are the key considerations when designing epitope-specific antibodies for DECR-1?

When developing epitope-specific antibodies for DECR-1, researchers should consider:

• Target epitope accessibility in native protein conformation

• Sequence uniqueness to avoid cross-reactivity with related proteins

• Epitope conservation across species if cross-species reactivity is desired

• Rational design approaches for targeting specific domains

The rational design method described by researchers involves identifying peptides complementary to target regions and grafting them onto antibody scaffolds . This approach is particularly valuable for creating antibodies against specific epitopes within disordered protein regions, which might be applicable to certain domains of DECR-1.

How should researchers approach antibody validation to ensure specificity for DECR-1?

A comprehensive validation strategy should include:

• Western blot analysis using known positive control tissues (kidney, pancreas, liver)

• Testing with recombinant DECR-1 protein as a standard

• Employing genetic approaches (siRNA knockdown, CRISPR-Cas9 knockout)

• Performing immunoprecipitation followed by mass spectrometry

• Conducting cross-reactivity testing against related family members

This multi-modal validation approach ensures that experimental results are specifically attributable to DECR-1 rather than cross-reactive proteins or non-specific binding.

How can researchers utilize DECR-1.3 antibody to investigate mitochondrial dysfunction in metabolic disorders?

DECR-1.3 antibody can be employed to:

• Quantify expression levels in patient samples with suspected fatty acid oxidation disorders

• Perform subcellular fractionation studies to assess mitochondrial localization

• Conduct immunoprecipitation to identify DECR-1 interaction partners

• Evaluate post-translational modifications affecting enzyme activity

• Monitor changes in expression following metabolic stress or therapeutic interventions

These approaches allow researchers to connect DECR-1 function to broader mitochondrial metabolism pathways and identify potential therapeutic targets in metabolic diseases.

What strategies can address contradictory results between DECR-1 protein detection and mRNA expression data?

When faced with discrepancies between protein and mRNA levels:

• Verify antibody specificity through additional validation approaches

• Consider post-transcriptional regulatory mechanisms

• Evaluate protein stability and turnover rates

• Assess technical variables in both protein and mRNA detection methods

• Examine temporal dynamics, as protein and mRNA levels may peak at different timepoints

Discrepancies often provide valuable insights into regulatory mechanisms rather than indicating experimental error.

How can researchers distinguish between closely related dehydrogenase/reductase family members?

To achieve specific detection among related proteins:

• Design epitope-specific antibodies targeting unique regions using rational design approaches

• Perform epitope mapping to identify antibody binding sites

• Utilize comparative protein expression analysis across multiple tissues

• Combine antibody-based detection with mass spectrometry for definitive identification

• Employ genetic tools like isoform-specific knockdown to confirm specificity

The rational design method described for creating antibodies against specific epitopes could be particularly valuable for distinguishing between closely related family members .

What approaches can resolve inconsistent DECR-1 detection in experimental samples?

When facing detection inconsistencies:

• Optimize protein extraction protocols specifically for mitochondrial proteins

• Evaluate sample handling and storage conditions to prevent degradation

• Test different membrane types and transfer conditions

• Adjust antibody concentration and incubation parameters

• Consider alternative blocking agents to reduce background

• Include protease and phosphatase inhibitors during sample preparation

Systematic troubleshooting focusing on each step of the experimental workflow will help identify and address specific variables affecting detection consistency.

How should researchers interpret variations in DECR-1 molecular weight across different experimental systems?

When encountering molecular weight variations:

• Consider post-translational modifications affecting migration patterns

• Evaluate different isoforms expressed in specific tissues or conditions

• Assess experimental variables including gel percentage, buffer systems, and running conditions

• Compare with recombinant protein standards of known molecular weight

• Investigate protein-protein interactions that may affect migration

The expected molecular weight of DECR-1 is approximately 34 kDa under reducing conditions , but variations may provide important biological insights rather than indicate technical issues.

What standards should researchers apply when quantifying relative or absolute DECR-1 levels?

For reliable quantification:

• Include calibration curves using recombinant DECR-1 protein standards

• Normalize to appropriate loading controls for relative quantification

• Apply digital image analysis with linear dynamic range validation

• Use multiple antibodies targeting different epitopes to confirm results

• Consider absolute quantification methods like ELISA or mass spectrometry

Quantitative analyses require rigorous standardization to ensure reproducibility and meaningful comparison across experimental conditions.

What are the key specifications for research-grade DECR-1 antibodies?

How do rational design approaches compare with traditional methods for developing epitope-specific antibodies?

Rational design approaches offer several advantages for developing epitope-specific antibodies:

The rational design method has been successfully applied to create antibodies targeting disordered proteins and peptides associated with neurodegenerative and systemic misfolding diseases .

How might DECR-1 antibodies contribute to understanding neurodegenerative disease mechanisms?

While DECR-1's primary role is in fatty acid metabolism, mitochondrial dysfunction is increasingly recognized in neurodegenerative conditions. Researchers could:

• Investigate DECR-1 expression in neuronal tissues from disease models

• Study relationships between DECR-1 activity and mitochondrial health in neurons

• Explore connections between fatty acid metabolism and neuroinflammation

• Apply rational antibody design approaches similar to those used for neurodegenerative disease proteins

• Develop therapeutic antibodies that modulate DECR-1 activity in specific neural cell populations

The methodologies used to design antibodies for neurodegenerative disease proteins could inform similar approaches for DECR-1 .

What emerging technologies might enhance DECR-1 detection sensitivity and specificity?

Promising technological advances include:

• Single-molecule detection methods for low-abundance samples

• Multiplexed immunoassays for simultaneous detection of DECR-1 and related proteins

• Antibody engineering approaches to increase affinity and reduce non-specific binding

• Computational methods for epitope prediction and antibody design

• Next-generation protein visualization techniques combining antibody detection with super-resolution microscopy